SM
DNTH icon

Sabby Management’s Dianthus Therapeutics DNTH Stock Holding History

Sabby Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,697
Closed -$611K – 94
2018
Q4 		$611K Buy
6,697
+808
+14% +$110K 0.13% 46
2018
Q3 		$1.13M Buy
5,889
+1,151
+24% +$242K 0.14% 51
2018
Q2 		$1.02M Buy
+4,738
New +$1.07M 0.16% 57

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Sabby Management's DNTH Position: Q1 2019 in Review

Sabby Management sold out of Dianthus Therapeutics (DNTH) in Q1 2019, closing a stake of 6,697 shares — an estimated $611K sold.

Sabby Management first reported a position in DNTH in Q2 2018 and held it in 3 quarters. The position peaked at $1.13M in Q3 2018. 63 funds tracked by Wall St. Rank hold DNTH as of Q1 2019.

  • Sabby Management reported no remaining Dianthus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Sabby Management sold 6,697 Dianthus Therapeutics shares in Q1 2019, an estimated $611K.
  • Sabby Management first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 3 quarters.
  • Sabby Management's Dianthus Therapeutics position peaked at $1.13M in Q3 2018.
  • 63 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.